Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yen Hsiu-Ju, Chen Shih-Hsiang, Chang Tsung-Yen, Yang Chao-Ping, Lin Dong-Tsamn, Hung Iou-Jih, Lin Kai-Hsin, Chen Jiann-Shiuh, Hsiao Chih-Cheng, Chang Tai-Tsung, Chang Te-Kao, Peng Ching-Tien, Lin Ming-Tsan, Jaing Tang-Her, Liu Hsi-Che, Jou Shiann-Tarng, Lu Meng-Yao, Cheng Chao-Neng, Sheen Jiunn-Ming, Chiou Shyh-Shin, Hung Giun-Yi, Wu Kang-Hsi, Yeh Ting-Chi, Wang Shih-Chung, Chen Rong-Long, Chang Hsiu-Hao, Yang Yung-Li, Chen Shu-Huey, Cheng Shin-Nan, Chang Yu-Hsiang, Chen Bow-Wen, Hsieh Yuh-Lin, Huang Fang-Liang, Ho Wan-Ling, Wang Jinn-Li, Chang Chia-Yau, Chao Yu-Hua, Lin Pei-Chin, Chen Yu-Chieh, Liao Yu-Mei, Lin Tung-Huei, Shih Lee-Yung, Liang Der-Cherng
Аннотация
PROCEDURE: In Taiwan Pediatric Oncology Group 2002 ALL studies, genotypes were determined by cytogenetic analysis and/or reverse transcriptase polymerase chain reaction assay. Based on presenting features, immunophenotype and genotype, patients were assigned to one of the three risk groups: standard risk (SR), high risk (HR), or very high risk (VHR). The patients with t(1;19)/TCF3-PBX1 were treated in the HR arm receiving more intensive chemotherapy. The outcomes of patients with t(1;19)/TCF3-PBX1 were compared to that of patients with other subtypes of B-precursor ALL (B-ALL).
RESULTS: Of the 1,129 patients with B-ALL, 64 (5.7%) had t(1;19)/TCF3-PBX1; 51 of whom were treated in the HR arm, but 11 were treated in the VHR and 2 in the SR arm because of physician's preference. As a group, 64 patients with t(1;19)/TCF3-PBX1 had similar 5-year event-free survival (83.3 ± 4.8%) as those with TEL-AML1 (85.2 ± 3.4%, P = 0.984) or those with hyperdiploidy >50 (84.0 ± 3.1%, P = 0.748). The cumulative risk of any (isolated plus combined) central nervous system relapse among patients with t(1;19)/TCF3-PBX1 (8.7 ± 3.8%) tended to be higher than that of patients with TEL-AML1 (5.8 ± 2.3%, P = 0.749) or those with hyperdiploidy (4.1 ± 1.8%, P = 0.135), albeit the differences did not reach statistical significance.
CONCLUSIONS: With contemporary intensive chemotherapy, children with t(1;19)/TCF3-PBX1 fared as well as those with favorable genotypes (TEL-AML1 or hyperdiploidy).